Quality of Sleep and Its Effect on Glycemic Control
Article Sidebar
Main Article Content
Abstract
Diabetes mellitus (DM) is a widespread illness that affects around 347 million individuals globally. DM not only has many clinical implications but also has a detrimental impact on the quality of sleep in patients. Insufficient sleep quality hinders the proper regulation of blood sugar levels, which is considered a fundamental aspect of managing diabetes. It also has other harmful repercussions that significantly affect one's overall quality of life. Increasing data suggests that sleep disturbances and sleep deprivation have an impact on glucose metabolism and insulin resistance. Simultaneously, changes in glucose metabolism can potentially affect the quality of sleep. The association between T2DM and sleep-disturbed breathing has been thoroughly investigated. Individuals diagnosed with T2DM exhibit a remarkably elevated incidence of obstructive sleep apnea, which subsequently leads to suboptimal management of blood sugar levels. Conversely, the correlation between T1DM and sleep has not been well-studied.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
American Diabetes Association Classification and diagnosis of diabetes: Standards of medical Care in diabetes-2018. Diabetes Care. 2018;41(Suppl 1):S13–S27.
Longo DL, Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. eighteenth ed. McGraw-Hill Medical; New York: 2013. Harrison' manual of medicine.
Zhuo X, Zhang P, Hoerger TJ. Lifetime direct medical costs of treating type 2 diabetes and diabetic complications. Am J Prev Med. 2013;45(3)
Shibabaw YY, Dejenie TA, Tesfa KH. Glycemic control and its association with sleep quality and duration among type 2 diabetic patients. Metabol Open. 2023;18:100246. Published 2023 May 19. doi:10.1016/j.metop.2023.100246
Dallaire A, Singh M. Anesthesiology. Springer; Cham: 2018. Anesthesia issues in patients with obstructive sleep apnea; pp. 719–727.
Lee SWH, Ng KY, Chin WK. The impact of sleep amount and sleep quality on glycemic control in type 2 diabetes: A systematic review and meta-analysis. Sleep Med Rev. 2017;31:91-101. doi:10.1016/j.smrv.2016.02.001
Botella-Serrano M, Velasco JM, Sánchez-Sánchez A, Garnica O, Hidalgo JI. Evaluating the influence of sleep quality and quantity on glycemic control in adults with type 1 diabetes. Front Endocrinol (Lausanne). 2023;14:998881. Published 2023 Feb 22. doi:10.3389/fendo.2023.998881
Sorkin JD, Muller DC, Fleg JL, et al. The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality: Data from the Baltimore longitudinal study of aging with a critical review of the literature. Diabetes Care 2005;28:2626–32.
Cavalot F, Pagliarino A, Valle M, et al. Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: Lessons from the San Luigi Gonzaga Diabetes Study. Diabetes Care 2011;34:2237–43.
Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. Lancet 2010;375:2215–22.
Martin CL, Albers J, Herman WH, et al. Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 2006;29:340–4.
Writing Group for the DCCT/EDIC Research Group, Orchard TJ, Nathan DM, et al. Association between 7 years of intensive treatment of type 1 diabetes and longterm mortality. JAMA 2015;313:45–53.
Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: The DCCT/EDIC study 30-year follow-up. Diabetes Care 2016;39:686–93.
Holman RR, Paul SK, Bethel MA, et al. 10-Year Follow-up of intensive glucose control in type 2 diabetes. New Engl J Med 2008;359:1577–89.
Irwin, M.R. Why sleep is important for health: A psychoneuroimmunology perspective. Annu. Rev. Psychol. 2015, 66, 143–172.
Paruthi, S.; Brooks, L.J.; D’Ambrosio, C.; Hall, W.A.; Kotagal, S.; Lloyd, R.M.; Malow, B.A.; Maski, K.; Nichols, C.; Quan, S.F.; et al. Recommended amount of sleep for pediatric populations: A consensus statement of the American Academy of Sleep Medicine. J. Clin. Sleep Med. 2016, 12, 785–786.
Kohyama, J. Factors Affecting the Quality of Sleep in Children. Children 2021, 8, 499.
Surani S, Brito V, Surani A, Ghamande S. Effect of diabetes mellitus on sleep quality. World J Diabetes. 2015;6(6):868-873. doi:10.4239/wjd.v6.i6.868
Luyster FS, Dunbar-Jacob J. Sleep quality and quality of life in adults with type 2 diabetes. Diabetes Educ. 2011;37:347–355.
Cizza G, Piaggi P, Lucassen EA, de Jonge L, Walter M, Mattingly MS, Kalish H, Csako G, Rother KI. Obstructive sleep apnea is a predictor of abnormal glucose metabolism in chronically sleep deprived obese adults. PLoS One. 2013;8:e65400.
Chasens ER, Korytkowski M, Sereika SM, Burke LE. Effect of poor sleep quality and excessive daytime sleepiness on factors associated with diabetes self-management. Diabetes Educ. 2013;39:74–82.
Amihăesei IC, Mungiu OC. Main neuroendocrine features and therapy in primary sleep troubles. Rev Med Chir Soc Med Nat Iasi. 2012;116:862–866.
Tian J, Dang H, Chen Z, Guan A, Jin Y, Atkinson MA, Kaufman DL. γ-Aminobutyric acid regulates both the survival and replication of human β-cells. Diabetes. 2013;62:3760–3765.
Rao MN, Neylan TC, Grunfeld C, Mulligan K, Schambelan M, Schwarz JM. Subchronic sleep restriction causes tissue-specific insulin resistance. J Clin Endocrinol Metab. 2015;100:1664–1671.
Bode BW, Schwartz S, Stubbs HA, Block JE. Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes: normative values. Diabetes Care. 2005;28:2361–2366.
Raju B, Arbelaez AM, Breckenridge SM, Cryer PE. Nocturnal hypoglycemia in type 1 diabetes: an assessment of preventive bedtime treatments. J Clin Endocrinol Metab. 2006;91:2087–2092.
Yki-Järvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care. 2000;23:1130–1136.
Benes H, Walters AS, Allen RP, Hening WA, Kohnen R. Definition of restless legs syndrome, how to diagnose it, and how to differentiate it from RLS mimics. Mov Disord. 2007;22 Suppl 18:S401–S408.
Greco D, Gambina F, Pisciotta M, Abrignani M, Maggio F. Clinical characteristics and associated comorbidities in diabetic patients with restless legs syndrome. Exp Clin Endocrinol Diabetes. 2009;117:496–499.
Cuellar NG, Ratcliffe SJ. A comparison of glycemic control, sleep, fatigue, and depression in type 2 diabetes with and without restless legs syndrome. J Clin Sleep Med. 2008;4:50–56.
Yeh P, Walters AS, Tsuang JW. Restless legs syndrome: a comprehensive overview on its epidemiology, risk factors, and treatment. Sleep Breath. 2012;16:987–1007.
Ohayon MM, O’Hara R, Vitiello MV. Epidemiology of restless legs syndrome: a synthesis of the literature. Sleep Med Rev. 2012;16:283–295.
Balachandran JS, Patel SR. In the clinic. Obstructive sleep apnea. Ann Intern Med. 2014;161:ITC1–I15; quiz ITC16.
Foster GD, Sanders MH, Millman R, Zammit G, Borradaile KE, Newman AB, Wadden TA, Kelley D, Wing RR, Sunyer FX, et al. Obstructive sleep apnea among obese patients with type 2 diabetes. Diabetes Care. 2009;32:1017–1019
Stamatakis K, Sanders MH, Caffo B, Resnick HE, Gottlieb DJ, Mehra R, Punjabi NM. Fasting glycemia in sleep disordered breathing: lowering the threshold on oxyhemoglobin desaturation. Sleep. 2008;31:1018–1024.